Selection of Resistant Mutations to Dolutegravir in PLWH Treated in Mozambique

This study is investigating whether HIV-positive patients in Mozambique who are taking first-line antiretroviral therapy (ART) — a regimen called TLD (tenofovir, lamivudine, dolutegravir) — are developing resistance mutations that could make their treatment stop working, even while they appear to be on therapy. **You may be eligible if...** - You are 18 years or older - You have documented HIV-1 infection - You have been on the TLD first-line ART regimen for at least 6 months - Your viral load has been above 200 copies/mL for at least 3 months despite being on treatment - You can understand and sign an informed consent form **You may NOT be eligible if...** - You are under 18 years of age - You are on a first-line regimen other than TLD - You have an active cancer or active opportunistic infections - You cannot give informed consent Talk to your doctor to see if this trial is right for you.